Johnson & Johnson $JNJ Shares Sold by Tweedy Browne Co LLC

Tweedy Browne Co LLC lowered its position in Johnson & Johnson (NYSE:JNJ) by 44.2% during the second quarter, according to its most recent Form 13F filing with the SEC. The fund owned 244,713 shares of the company’s stock after selling 193,558 shares during the period. Johnson & Johnson accounts for 3.5% of Tweedy Browne Co LLC’s portfolio, making the stock its 8th largest holding. Tweedy Browne Co LLC’s holdings in Johnson & Johnson were worth $37,380,000 at the end of the most recent quarter.

A number of other institutional investors have also recently added to or reduced their stakes in the business. Arista Wealth Management LLC bought a new stake in Johnson & Johnson in the second quarter worth approximately $1,489,000. Sage Private Wealth Group LLC boosted its holdings in Johnson & Johnson by 13.0% in the second quarter. Sage Private Wealth Group LLC now owns 3,304 shares of the company’s stock worth $505,000 after purchasing an additional 381 shares in the last quarter. Stratos Investment Management LLC increased its position in Johnson & Johnson by 5.8% during the second quarter. Stratos Investment Management LLC now owns 19,948 shares of the company’s stock worth $3,047,000 after buying an additional 1,094 shares during the last quarter. Oxbow Advisors LLC boosted its stake in shares of Johnson & Johnson by 2.9% during the 2nd quarter. Oxbow Advisors LLC now owns 44,663 shares of the company’s stock worth $6,822,000 after acquiring an additional 1,258 shares in the last quarter. Finally, Smithbridge Asset Management Inc. DE lifted its holdings in Johnson & Johnson by 1.7% in the 2nd quarter. Smithbridge Asset Management Inc. DE now owns 41,967 shares of the company’s stock worth $6,410,000 after purchasing an additional 686 shares during the last quarter. 69.55% of the stock is currently owned by institutional investors and hedge funds.

Johnson & Johnson Stock Performance

Shares of NYSE JNJ opened at $193.27 on Friday. The firm has a market capitalization of $465.45 billion, a price-to-earnings ratio of 18.65, a PEG ratio of 2.27 and a beta of 0.40. Johnson & Johnson has a one year low of $140.68 and a one year high of $194.40. The business has a fifty day simple moving average of $180.49 and a 200 day simple moving average of $164.86. The company has a current ratio of 1.01, a quick ratio of 0.76 and a debt-to-equity ratio of 0.50.

Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings results on Wednesday, August 30th. The company reported $2.26 earnings per share (EPS) for the quarter. Johnson & Johnson had a net margin of 27.26% and a return on equity of 33.08%. The firm had revenue of $24.02 billion for the quarter. Sell-side analysts expect that Johnson & Johnson will post 10.58 EPS for the current year.

Johnson & Johnson Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 9th. Shareholders of record on Tuesday, November 25th will be paid a dividend of $1.30 per share. The ex-dividend date is Tuesday, November 25th. This represents a $5.20 dividend on an annualized basis and a yield of 2.7%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 50.19%.

Analyst Ratings Changes

JNJ has been the topic of a number of recent analyst reports. Guggenheim raised shares of Johnson & Johnson from a “neutral” rating to a “buy” rating and lifted their price target for the company from $167.00 to $206.00 in a research report on Tuesday, September 23rd. Royal Bank Of Canada reiterated an “outperform” rating and issued a $209.00 target price on shares of Johnson & Johnson in a report on Friday, October 10th. Wall Street Zen upgraded shares of Johnson & Johnson from a “hold” rating to a “buy” rating in a report on Saturday, September 13th. Raymond James Financial increased their target price on Johnson & Johnson from $174.00 to $209.00 and gave the company an “outperform” rating in a research note on Wednesday. Finally, Weiss Ratings upgraded Johnson & Johnson from a “hold (c+)” rating to a “buy (b-)” rating in a report on Wednesday, October 8th. Two equities research analysts have rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and eight have given a Hold rating to the company. Based on data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $199.59.

Insiders Place Their Bets

In other Johnson & Johnson news, EVP Jennifer L. Taubert sold 56,471 shares of Johnson & Johnson stock in a transaction that occurred on Thursday, September 4th. The stock was sold at an average price of $177.81, for a total transaction of $10,041,108.51. Following the sale, the executive vice president directly owned 178,013 shares of the company’s stock, valued at approximately $31,652,491.53. The trade was a 24.08% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Insiders own 0.16% of the company’s stock.

Johnson & Johnson Company Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.